跳至主要内容
临床试验/CTRI/2014/09/005014
CTRI/2014/09/005014招募中未知

â??A 12 week, prospective, open-label, randomized controlled clinical trial, comparing indigenized Negative Pressure Device (NPD) to standard wound care for the treatment of bedsores in traumatic paraplegia patients. - NPWT (Negative pressure wound therapy)

Council of Science Technology0 个研究点目标入组 54 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
招募中
发起方
入组人数
54

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Sacral pressure sores in traumatic paraplegia patients with no signs of improvement and healing.
  • 2.Stage III-IV pressure ulcer according to the National Pressure Ulcer Advisory Panel (NPUAP)
  • 3.No clinical signs of active infection at the wound site and currently not on antibiotics.
  • 4. Patients to give informed consent.

排除标准

  • 1.Candidate for surgery.
  • 2.A wound with necrotic tissue unable to tolerate debridement.
  • 3.Exposed blood vessels within the wound.
  • 4.Chronic osteomyelitis (as determined by biopsy) or osteomyelitis that is not treatable by debridement and antibiotics.
  • 5.Non-enteric or unexplored fistulae.
  • 6.Wounds requiring homeostasis (i.e., that the flow of blood be stopped) for local bleeding.
  • 7.Alternate etiology for non-healing.
  • 8.Concomitant conditions that in the judgment of the investigator would make the subject inappropriate for entry to the study (e.g., malignancy in wound, malignancy less than 1-year disease free interval, previous or current irradiation, known immunodeficiency and/or major uncorrected medical disorders such as serious non-malignant disease, serious cardiovascular or pulmonary disease, lupus, inflammatory bowel disease, palliative care or sickle cell disease)
  • 9.Poor nutritional status as determined by a Braden Scale Nutritional Assessment score of 2 or 1 with a serum albumin < 2.5 g/L and hemoglobin < 9.0 g/L.
  • 10.Currently taking medication that may interfere with wound healing (e.g., oral systemic steroids, immunosuppressive drugs, unfractionated heparin infusion)
  • 11.Women who are currently pregnant or are breast feeding; or women of child bearing potential who are not currently taking adequate birth control

研究者

发起方
Council of Science Technology

相似试验

进行中(未招募)
1 期
A 12-Month Clinical Research Study to evaluate a new investigational medication (siplizumab) compared to another medication (anti-thymocyte globulin) for the prevention of rejection in patients who have received a kidney transplant.renal transplantationMedDRA version: 21.1Level: LLTClassification code 10050436Term: Prophylaxis against renal transplant rejectionSystem Organ Class: 100000004865
EUCTR2020-000419-56-SEITB-MED AB40
进行中(未招募)
1 期
A 12-Month Clinical Research Study to evaluate a new investigational medication (siplizumab) compared to another medication (anti-thymocyte globulin) for the prevention of rejection in patients who have received a kidney transplant.renal transplantationMedDRA version: 21.1Level: LLTClassification code 10050436Term: Prophylaxis against renal transplant rejectionSystem Organ Class: 100000004865
EUCTR2020-000419-56-ATITB-MED AB40
进行中(未招募)
不适用
A 12-month, multicenter, randomized, open-label non-inferiority study of renal function and efficacy comparing concentration-controlled Certican (1.5 mg/day starting dose) with reduced Neoral dose versus MMF with standard Neoral dose in de novo heart transplant recipientsProphylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogeneic cardiac transplant. The drug should be used in combination with ciclosporin for microemulsion and corticosteroids.MedDRA version: 6.1Level: PTClassification code 10019315
EUCTR2004-001052-36-ITOVARTIS FARMA
进行中(未招募)
1 期
Study to evaluate renal function of everolimus plus tacrolimus in liver transplant patientsliver transplantationMedDRA version: 20.0Level: LLTClassification code 10024716Term: Liver transplantationSystem Organ Class: 100000004865
EUCTR2011-003118-17-DEovartis Pharma GmbH
进行中(未招募)
1 期
A 12-month, multicenter, open label, randomized, controlled study to evaluate the efficacy, tolerability and safety of early introduction of everolimus, reduced CNI, and early steroid elimination compared to standard CNI, mycophenolate mofetil and steroid regimen in paediatric renal transplant recipients with a 24-month additional safety follow-up.Prevention of acute rejection in paediatric recipients of a renal transplantMedDRA version: 14.1Level: PTClassification code 10038533Term: Renal transplantSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 14.1Level: LLTClassification code 10023438Term: Kidney transplantSystem Organ Class: 10042613 - Surgical and medical procedures
EUCTR2010-024381-21-ITOVARTIS FARMA106